Rockwell Medical Earnings Reports

Rockwell Medical delivered strong fourth-quarter results with a notable 12% increase in net sales, improved gross profit, and a narrowed net loss compared to the prior year. The company achieved profitability on an adjusted EBITDA basis and introduced significant agreements positioning it for future growth.

Rockwell Medical reported a strong third quarter in 2024, marked by increased net product sales, significant growth in gross profit, and a return to profitability. The company's net sales reached $28.3 million, driven by a large order of premium-priced products, and it generated $4.3 million in cash flow from operations.

Rockwell Medical reported record net sales of $22.7 million for Q1 2024, a 15% increase year-over-year. Gross profit also reached a record $3.1 million, up 18% from the same period last year. The company has raised its full-year 2024 guidance for net sales, gross profit, and adjusted EBITDA.

Rockwell Medical reported achieving profitability on an adjusted EBITDA basis in Q4 2023, alongside record net sales, gross profit, and gross margin for the full year 2023. The company has focused on improving financial health, securing multi-year agreements, expanding geographically, and improving manufacturing efficiencies.

Rockwell Medical announced its Q3 2023 results, highlighting its success in becoming the leading supplier of liquid bicarbonate hemodialysis concentrates in the US and its expectation to be profitable on an adjusted EBITDA basis in Q4 2023. The company also expects net sales for 2023 to be between $82.0 million and $86.0 million, representing a 17% to 18% year-over-year increase, and gross profit to be between $8.0 million and $10.0 million, representing a 95% to 144% year-over-year increase.

Rockwell Medical reported net sales of $18.1 million for the second quarter of 2023, a decrease compared to Q2 2022. The company's net loss decreased to $3.3 million, or $0.18 per share, compared to a net loss of $5.0 million, or $0.43 per share for the same period in 2022. The company also acquired Evoqua Water Technologies' hemodialysis concentrates business.

Rockwell Medical reported a 22.4% increase in revenue, reaching $19.7 million, and a significant improvement in gross profit, which increased by 425% compared to the same period last year. The company also reduced its operating expenses, leading to a reduced operating loss and net loss. They reiterate 2023 revenue guidance of $78.0 million to $82.0 million and gross profit between $7.0 million and $9.0 million.

Rockwell Medical reported a 26.0% increase in revenue for the fourth quarter of 2022, reaching $19.3 million, and a net loss of $2.4 million, or $0.20 per share. The company's cash used in operating activities decreased significantly to $594,000. They exceeded annual revenue guidance generating $72.8 million in 2022.

Rockwell Medical reported revenue of $18.7 million for the third quarter of 2022, the highest quarterly revenue to date, and reduced cash used in operating activities by 81% compared to the previous quarter. The company is restructuring its business to focus on revenue-generating businesses and expects to achieve profitability in 2024.

Rockwell Medical announced its second quarter 2022 results, reporting revenue of $18.7 million, a 24% increase year-over-year. The company achieved a gross profit of $1.7 million compared to a gross loss in the previous quarter and raised $30 million in financing.

Rockwell Medical reported first quarter net sales of $16.1 million, a 4.2% increase year-over-year. The company amended and expanded its supply agreement with DaVita, including a $7.5 million investment, and completed patient enrollment ahead of schedule in a pivotal Phase 3 trial of Triferic® in China.

Rockwell Medical reported a strong third quarter with net sales of $16.0 million, a 6% increase sequentially and a 5% increase year-over-year. The growth was primarily driven by an increase in sales of dialysis concentrates products. The company also submitted an Investigational New Drug application with the FDA for its proposed clinical trial of FPC as a treatment for iron deficiency anemia in patients receiving home infusion.

Rockwell Medical reported first quarter 2021 financial results, with revenues of $15.5 million. The company is progressing with its Home Infusion FPC program and received marketing approval in Canada for Triferic AVNU™.

Rockwell Medical reported Q4 2020 revenues of $15.2 million compared to $15.5 million for the same quarter of the previous year. Net loss was $8.7 million, or $(0.09) basic and diluted net loss per share, compared to a net loss of $7.3 million, or $(0.11) basic and diluted net loss per share, for the same period in 2019. The company ended the year with $58.7 million in cash, cash equivalents and investments.

Rockwell Medical reported Q3 2020 revenue of $15.3 million and ended the quarter with $67.3 million in cash, cash equivalents and investments. The company is preparing for the U.S. commercial launch of Triferic® AVNU expected in Q1 2021 and anticipates enrolling the first patient in a Phase 3 clinical trial of Triferic in China.

Rockwell Medical reported a 7.1% increase in net sales for the second quarter of 2020, primarily due to increased demand for dialysis concentrates products, and made progress in the commercialization of Triferic Dialysate despite COVID-19 challenges.

Rockwell Medical reported a 2% increase in net sales for Q1 2020, driven by Triferic Dialysate sales. The company also received FDA approval for Triferic AVNU and strengthened its financial position with $48.9 million in cash, cash equivalents, and marketable securities.

Rockwell Medical reported a net loss of $7.3 million on net sales of $15.5 million for the fourth quarter of 2019. The company saw a decrease in net sales compared to the same period in 2018, but also a reduction in general and administrative expenses.